Rethinking ovarian cancer III: the past decade and future directions

Area of Science:

• Oncology
• Genetics
• Gynecologic Oncology

Background:

• High-grade serous carcinoma (HGSC) accounts for approximately 80% of ovarian cancer mortality.
• HGSC is characterized by high chromosomal instability and a high prevalence of BRCA1/BRCA2 mutations.
• Despite advances in targeted therapies and surgery, 5-year survival rates remain suboptimal, particularly for advanced-stage disease without BRCA1/BRCA2 mutations.

Purpose of the Study:

• To review recent advances in HGSC research and treatment.
• To identify current challenges and emerging technologies in HGSC prevention, early detection, and therapy.
• To establish research priorities for the future of HGSC management.

Main Methods:

• Expert recommendations derived from discussions at the 15th Helene Harris Memorial Trust International Forum on ovarian cancer.
• Consideration of research and treatment progress over the past decade.
• Evaluation of emerging technologies and future research directions.

Main Results:

• Significant progress has been made in understanding HGSC biology and developing targeted therapies.
• Challenges persist in improving survival rates, especially for patients with advanced or BRCA1/BRCA2 wild-type disease.
• Emerging technologies offer potential for improved prevention, earlier detection, and more effective treatments.

Conclusions:

• Continued research is crucial to overcome current treatment limitations in HGSC.
• Focus on prevention, early detection, and novel therapeutic strategies is essential.
• Collaborative efforts and investment in research are needed to improve outcomes for ovarian cancer patients.